{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:49:01Z","timestamp":1789523341768,"version":"build-2803163510"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Pfizer Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s10620-020-06560-4","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T09:04:01Z","timestamp":1597914241000},"page":"2732-2743","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials"],"prefix":"10.1007","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5247-940X","authenticated-orcid":false,"given":"Remo","family":"Panaccione","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea Ann","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Marren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisy","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinyu","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,20]]},"reference":[{"key":"6560_CR1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40169-016-0114-5","volume":"5","author":"D Kitzenberg","year":"2016","unstructured":"Kitzenberg D, Colgan SP, Glover LE. Creatine kinase in ischemic and inflammatory disorders. Clin Transl Med. 2016;5:31.","journal-title":"Clin Transl Med"},{"key":"6560_CR2","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1468-1331.2010.03012.x","volume":"17","author":"T Kyriakides","year":"2010","unstructured":"Kyriakides T, Angelini C, Schaefer J, et al. EFNS guidelines on the diagnostic approach to pauci- or asymptomatic hyperCKemia. Eur J Neurol. 2010;17:767\u2013773.","journal-title":"Eur J Neurol"},{"key":"6560_CR3","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s11739-007-0060-8","volume":"2","author":"WH Bagley","year":"2007","unstructured":"Bagley WH, Yang H, Shah KH. Rhabdomyolysis. Intern Emerg Med. 2007;2:210\u2013218.","journal-title":"Intern Emerg Med"},{"key":"6560_CR4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3949\/ccjm.83a.14120","volume":"83","author":"S Moghadam-Kia","year":"2016","unstructured":"Moghadam-Kia S, Oddis CV, Aggarwal R. Approach to asymptomatic creatine kinase elevation. Cleve Clin J Med. 2016;83:37\u201342.","journal-title":"Cleve Clin J Med"},{"key":"6560_CR5","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/ajcp\/79.5.582","volume":"79","author":"ET Wong","year":"1983","unstructured":"Wong ET, Cobb C, Umehara MK, et al. Heterogeneity of serum creatine kinase activity among racial and gender groups of the population. Am J Clin Pathol. 1983;79:582\u2013586.","journal-title":"Am J Clin Pathol"},{"key":"6560_CR6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.amjmed.2008.08.033","volume":"122","author":"RC Neal","year":"2009","unstructured":"Neal RC, Ferdinand KC, Ycas J, Miller E. Relationship of ethnic origin, gender, and age to blood creatine kinase levels. Am J Med. 2009;122:73\u201378.","journal-title":"Am J Med"},{"key":"6560_CR7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/bmb\/ldm014","volume":"81\u201382","author":"P Brancaccio","year":"2007","unstructured":"Brancaccio P, Maffulli N, Limongelli FM. Creatine kinase monitoring in sport medicine. Br Med Bull. 2007;81\u201382:209\u2013230.","journal-title":"Br Med Bull"},{"key":"6560_CR8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0009-8981(98)00180-6","volume":"279","author":"EI Lev","year":"1999","unstructured":"Lev EI, Tur-Kaspa I, Ashkenazy I, et al. Distribution of serum creatine kinase activity in young healthy persons. Clin Chim Acta. 1999;279:107\u2013115.","journal-title":"Clin Chim Acta"},{"key":"6560_CR9","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.nmd.2011.04.007","volume":"21","author":"H Lilleng","year":"2011","unstructured":"Lilleng H, Abeler K, Johnsen SH, et al. Variation of serum creatine kinase (CK) levels and prevalence of persistent hyperCKemia in a Norwegian normal population. The Troms\u00f8 study. Neuromuscul Disord. 2011;21:494\u2013500.","journal-title":"Neuromuscul Disord"},{"key":"6560_CR10","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ahj.2007.06.008","volume":"154","author":"LM Brewster","year":"2007","unstructured":"Brewster LM, Mairuhu G, Sturk A, van Montfrans GA. Distribution of creatine kinase in the general population: implications for statin therapy. Am Heart J. 2007;154:655\u2013661.","journal-title":"Am Heart J"},{"key":"6560_CR11","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jaad.2016.01.013","volume":"74","author":"KA Papp","year":"2016","unstructured":"Papp KA, Krueger JG, Feldman SR, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. J Am Acad Dermatol. 2016;74:841\u2013850.","journal-title":"J Am Acad Dermatol"},{"key":"6560_CR12","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723\u20131736.","journal-title":"N Engl J Med"},{"key":"6560_CR13","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","volume":"377","author":"D Gladman","year":"2017","unstructured":"Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377:1525\u20131536.","journal-title":"N Engl J Med"},{"key":"6560_CR14","unstructured":"US Food and Drug Administration. OLUMIANT (baricitinib): Highlights of Prescribing Information. 2018. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/207924s000lbl.pdf. Accessed June 5, 2019."},{"key":"6560_CR15","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Ghosh S, Panes J, et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology. 2020;158:2139\u20132149.","journal-title":"Gastroenterology"},{"key":"6560_CR16","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","volume":"394","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde D, Song IH, Pangan AL, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial. Lancet. 2019;394:2108\u20132117.","journal-title":"Lancet"},{"key":"6560_CR17","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","volume":"71","author":"R Fleischmann","year":"2019","unstructured":"Fleischmann R, Pangan AL, Song IH, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol. 2019;71:1788\u20131800.","journal-title":"Arthritis Rheumatol"},{"key":"6560_CR18","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/bjd.13551","volume":"172","author":"R Bissonnette","year":"2015","unstructured":"Bissonnette R, Iversen L, Sofen H, et al. Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial. Br J Dermatol. 2015;172:1395\u20131406.","journal-title":"Br J Dermatol"},{"key":"6560_CR19","doi-asserted-by":"crossref","first-page":"R158","DOI":"10.1186\/ar4673","volume":"16","author":"JD Isaacs","year":"2014","unstructured":"Isaacs JD, Zuckerman A, Krishnaswami S, et al. Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials. Arthritis Res Ther. 2014;16:R158.","journal-title":"Arthritis Res Ther"},{"key":"6560_CR20","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/ibd\/izy088","volume":"24","author":"E Theodoraki","year":"2018","unstructured":"Theodoraki E, Orfanoudaki E, Foteinogiannopoulou K, Koutroubakis IE. Asymptomatic hyperCKemia during infliximab therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2018;24:1266\u20131271.","journal-title":"Inflamm Bowel Dis"},{"key":"6560_CR21","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.cgh.2012.06.032","volume":"10","author":"I Ord\u00e1s","year":"2012","unstructured":"Ord\u00e1s I, Feagan BG, Sandborn WJ. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2012;10:1079\u20131087.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"6560_CR22","first-page":"5329","volume":"113","author":"GR Lichtenstein","year":"2018","unstructured":"Lichtenstein GR, Loftus EV Jr, Bloom S, et al. Tofacitinib, an oral Janus kinase inhibitor, in the treatment of ulcerative colitis: an interim analysis of an open-label, long-term extension study with up to 49\u00a0years of treatment [abstract]. Am J Gastroenterol. 2018;113:5329.","journal-title":"Am J Gastroenterol"},{"key":"6560_CR23","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/art.38974","volume":"67","author":"C Charles-Schoeman","year":"2015","unstructured":"Charles-Schoeman C, Fleischmann R, Davignon J, et al. Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. Arthritis Rheumatol. 2015;67:616\u2013625.","journal-title":"Arthritis Rheumatol"},{"key":"6560_CR24","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13075-015-0612-7","volume":"17","author":"JM Kremer","year":"2015","unstructured":"Kremer JM, Kivitz AJ, Simon-Campos JA, et al. Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial. Arthritis Res Ther. 2015;17:95.","journal-title":"Arthritis Res Ther"},{"key":"6560_CR25","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/art.24567","volume":"60","author":"JM Kremer","year":"2009","unstructured":"Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 2009;60:1895\u20131905.","journal-title":"Arthritis Rheum"},{"key":"6560_CR26","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/art.33419","volume":"64","author":"JM Kremer","year":"2012","unstructured":"Kremer JM, Cohen S, Wilkinson BE, et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum. 2012;64:970\u2013981.","journal-title":"Arthritis Rheum"},{"key":"6560_CR27","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/art.33383","volume":"64","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R, Cutolo M, Genovese MC, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum. 2012;64:617\u2013629.","journal-title":"Arthritis Rheum"},{"key":"6560_CR28","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/acr.20494","volume":"63","author":"Y Tanaka","year":"2011","unstructured":"Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH, Tofacitinib Study Investigators. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res Hoboken. 2011;63:1150\u20131158.","journal-title":"Arthritis Care Res Hoboken"},{"key":"6560_CR29","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3109\/14397595.2014.995875","volume":"25","author":"Y Tanaka","year":"2015","unstructured":"Tanaka Y, Takeuchi T, Yamanaka H, Nakamura H, Toyoizumi S, Zwillich S. Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study. Mod Rheumatol. 2015;25:514\u2013521.","journal-title":"Mod Rheumatol"},{"key":"6560_CR30","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/annrheumdis-2012-202442","volume":"73","author":"IB McInnes","year":"2014","unstructured":"McInnes IB, Kim HY, Lee SH, et al. Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study. Ann Rheum Dis. 2014;73:124\u2013131.","journal-title":"Ann Rheum Dis"},{"key":"6560_CR31","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1136\/annrheumdis-2015-208267","volume":"75","author":"PG Conaghan","year":"2016","unstructured":"Conaghan PG, \u00d8stergaard M, Bowes MA, et al. Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques. Ann Rheum Dis. 2016;75:1024\u20131033.","journal-title":"Ann Rheum Dis"},{"key":"6560_CR32","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1136\/annrheumdis-2014-206028","volume":"74","author":"DL Boyle","year":"2015","unstructured":"Boyle DL, Soma K, Hodge J, et al. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Ann Rheum Dis. 2015;74:1311\u20131316.","journal-title":"Ann Rheum Dis"},{"key":"6560_CR33","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/annrheumdis-2014-207191","volume":"75","author":"KL Winthrop","year":"2016","unstructured":"Winthrop KL, Silverfield J, Racewicz A, et al. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis. 2016;75:687\u2013695.","journal-title":"Ann Rheum Dis"},{"key":"6560_CR34","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/art.40187","volume":"69","author":"KL Winthrop","year":"2017","unstructured":"Winthrop KL, Wouters AG, Choy EH, et al. The safety and immunogenicity of live zoster vaccination in patients with rheumatoid arthritis before starting tofacitinib: a randomized phase II trial. Arthritis Rheumatol. 2017;69:1969\u20131977.","journal-title":"Arthritis Rheumatol"},{"key":"6560_CR35","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","volume":"381","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381:451\u2013460.","journal-title":"Lancet"},{"key":"6560_CR36","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.37816","volume":"65","author":"D van der Heijde","year":"2013","unstructured":"van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65:559\u2013570.","journal-title":"Arthritis Rheum"},{"key":"6560_CR37","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","volume":"367","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495\u2013507.","journal-title":"N Engl J Med"},{"key":"6560_CR38","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","volume":"159","author":"J Kremer","year":"2013","unstructured":"Kremer J, Li Z-G, Hall S, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013;159:253\u2013261.","journal-title":"Ann Intern Med"},{"key":"6560_CR39","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","volume":"367","author":"RF van Vollenhoven","year":"2012","unstructured":"van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508\u2013519.","journal-title":"N Engl J Med"},{"key":"6560_CR40","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370:2377\u20132386.","journal-title":"N Engl J Med"},{"key":"6560_CR41","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","volume":"390","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017;390:457\u2013468.","journal-title":"Lancet"},{"key":"6560_CR42","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3899\/jrheum.130683","volume":"41","author":"J Wollenhaupt","year":"2014","unstructured":"Wollenhaupt J, Silverfield J, Lee EB, et al. Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol. 2014;41:837\u2013852.","journal-title":"J Rheumatol"},{"key":"6560_CR43","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13075-016-0932-2","volume":"18","author":"H Yamanaka","year":"2016","unstructured":"Yamanaka H, Tanaka Y, Takeuchi T, et al. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Res Ther. 2016;18:34.","journal-title":"Arthritis Res Ther"},{"key":"6560_CR44","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/art.39972","volume":"69","author":"J Wollenhaupt","year":"2017","unstructured":"Wollenhaupt J, Silverfield J, Lee EB, et al. Tofacitinib, an oral Janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 9\u00a0years [abstract]. Arthritis Rheumatol. 2017;69:683\u2013684.","journal-title":"Arthritis Rheumatol"},{"key":"6560_CR45","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.jaci.2015.12.1318","volume":"137","author":"J Krueger","year":"2016","unstructured":"Krueger J, Clark JD, Su\u00e1rez-Fari\u00f1as M, et al. Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: a randomized phase 2 study. J Allergy Clin Immunol. 2016;137:1079\u20131090.","journal-title":"J Allergy Clin Immunol"},{"key":"6560_CR46","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1365-2133.2012.11168.x","volume":"167","author":"KA Papp","year":"2012","unstructured":"Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012;167:668\u2013677.","journal-title":"Br J Dermatol"},{"key":"6560_CR47","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.14018","volume":"173","author":"KA Papp","year":"2015","unstructured":"Papp KA, Menter MA, Abe M, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two, randomized, placebo-controlled, phase III trials. Br J Dermatol. 2015;173:949\u2013961.","journal-title":"Br J Dermatol"},{"key":"6560_CR48","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","volume":"386","author":"H Bachelez","year":"2015","unstructured":"Bachelez H, van de Kerkhof PC, Strohal R, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet. 2015;386:552\u2013561.","journal-title":"Lancet"},{"key":"6560_CR49","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","volume":"377","author":"P Mease","year":"2017","unstructured":"Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377:1537\u20131550.","journal-title":"N Engl J Med"},{"key":"6560_CR50","first-page":"682","volume":"76","author":"P Nash","year":"2017","unstructured":"Nash P, Coates LC, Kivitz AJ, et al. Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, up to 24\u00a0months in patients with active psoriatic arthritis: interim data from OPAL balance, an open-label, long-term extension study [abstract]. Ann Rheum Dis. 2017;76:682.","journal-title":"Ann Rheum Dis"},{"key":"6560_CR51","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13054-016-1314-5","volume":"20","author":"LO Chavez","year":"2016","unstructured":"Chavez LO, Leon M, Einav S, Varon J. Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice. Crit Care. 2016;20:135.","journal-title":"Crit Care"}],"updated-by":[{"DOI":"10.1007\/s10620-020-06638-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T00:00:00Z","timestamp":1602288000000}}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-020-06560-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-020-06560-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-020-06560-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T23:05:14Z","timestamp":1629414314000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-020-06560-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,20]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["6560"],"URL":"https:\/\/doi.org\/10.1007\/s10620-020-06560-4","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10620-020-06638-z","asserted-by":"object"}]},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,20]]},"assertion":[{"value":"4 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10620-020-06638-z","URL":"https:\/\/doi.org\/10.1007\/s10620-020-06638-z","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"RP has received consulting fees from AbbVie, Amgen, Aptalis, AstraZeneca, Baxter, Biogen, Bristol-Myers Squibb, Celgene, Centocor, Cubist, Eisai, Elan, Ferring, Gilead, GlaxoSmithKline, Janssen, Merck, Pfizer Inc, Robarts Clinical Trials, Salix, Samsung Bioepis, Shire, Takeda, and UCB; has received research Grants from AbbVie, Ferring, Janssen, and Takeda; has received lectures and\/or speaker bureau fees from AbbVie, Aptalis, AstraZeneca, Ferring, Janssen, Merck, Prometheus, Shire, and Takeda; and has received advisory board fees from Abbott, AbbVie, Amgen, Aptalis, AstraZeneca, Baxter, Bristol-Myers Squibb, Celgene, Centocor, Cubist, Eisai, Elan, Ferring, Genentech, GlaxoSmithKline, Janssen, Merck, Pfizer Inc, Salix, Schering-Plough, Shire, Takeda, and UCB. JDI has been a consultant for, and\/or has received research Grants or speaker fees from, AbbVie, Amgen, Eli Lilly, Gilead, Merck, Pfizer Inc, Roche, and UCB. LAC has served as a consultant for Pfizer Inc; has received research Grants from BioRad, Pfizer Inc, and PredictImmune; and has received advisory board fees from Gilead and Janssen. WW, AM, KK, LW, GC, and CS are employees and stockholders of Pfizer Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"These data were presented at the 2018 Annual Scientific Meeting of the American College of Gastroenterology, Philadelphia, PA, USA, October 5\u201310, 2018.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conference presentation"}},{"value":"All studies received appropriate Institutional Review Board and\/or Independent Ethics Committee approval. All patients provided written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}